You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Harvard Business School
Johnson and Johnson
Merck
Colorcon

Last Updated: February 29, 2020

DrugPatentWatch Database Preview

ANGIOMAX Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Angiomax, and when can generic versions of Angiomax launch?

Angiomax is a drug marketed by Sandoz Inc and Maia Pharms Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ANGIOMAX is bivalirudin. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.

US ANDA Litigation and Generic Entry Outlook for Angiomax

A generic version of ANGIOMAX was approved as bivalirudin by HOSPIRA INC on July 14th, 2015.

  Start Trial

Drug patent expirations by year for ANGIOMAX
Drug Prices for ANGIOMAX

See drug prices for ANGIOMAX

Recent Clinical Trials for ANGIOMAX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pacific UniversityPhase 4
Legacy Health SystemPhase 4
Qian GongPhase 2

See all ANGIOMAX clinical trials

Recent Litigation for ANGIOMAX

Identify potential future generic entrants

District Court Litigation
Case NameDate
Medicines Company v. Hospira, Inc.2014-05-13
The Medicines Company v. Exela Pharma Sciences, LLC2014-04-25
THE MEDICINES COMPANY v. AUROBINDO PHARMA LIMITED2014-04-11

See all ANGIOMAX litigation

Pharmacology for ANGIOMAX
Synonyms for ANGIOMAX
(R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine
1191386-55-6
128270-60-0
270B600
70B600
AKOS015994644
AN-7543
Angiox
BC657176
BG 8967
BG-8967
BG8967
Bivalirudin
Bivalirudin [USAN:BAN:INN]
Bivalirudin [USAN:INN:BAN]
Bivalirudin Trifluoacetate
Bivalirudin Trifluoroacetate
Bivalirudin;0.9% Sodium Chloride
bivalirudina
bivalirudine
bivalirudinum
C98H138N24O33
C9H11NO.C2H6.CH4
CHEBI:59173
CHEMBL2103749
DB00006
EBD32115
GTPL6470
Hirulog
Hirulog-1
HS-2004
J-005587
KS-00002WUN
LS-172701
MolPort-006-167-455
Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen
Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64)
SCHEMBL25739
TN9BEX005G
UNII-TN9BEX005G
Paragraph IV (Patent) Challenges for ANGIOMAX
Tradename Dosage Ingredient NDA Submissiondate
ANGIOMAX INJECTABLE;INTRAVENOUS bivalirudin 020873 2009-09-01

US Patents and Regulatory Information for ANGIOMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sandoz Inc ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873-001 Dec 15, 2000 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Maia Pharms Inc ANGIOMAX RTU bivalirudin SOLUTION;INTRAVENOUS 211215-001 Jul 25, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Medtronic
AstraZeneca
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.